241 related articles for article (PubMed ID: 15528069)
21. Dose rate constants for 125I, 103Pd, 192Ir and 169Yb brachytherapy sources: an EGS4 Monte Carlo study.
Mainegra E; Capote R; López E
Phys Med Biol; 1998 Jun; 43(6):1557-66. PubMed ID: 9651025
[TBL] [Abstract][Full Text] [Related]
22. Monte Carlo-aided dosimetry of the theragenics TheraSeed model 200 103Pd interstitial brachytherapy seed.
Monroe JI; Williamson JF
Med Phys; 2002 Apr; 29(4):609-21. PubMed ID: 11991133
[TBL] [Abstract][Full Text] [Related]
23. Monte Carlo calculation of the TG-43 dosimetric parameters of a new BEBIG Ir-192 HDR source.
Granero D; Pérez-Calatayud J; Ballester F
Radiother Oncol; 2005 Jul; 76(1):79-85. PubMed ID: 16019091
[TBL] [Abstract][Full Text] [Related]
24. Dosimetric characteristics of the bests double-wall 103Pd brachytherapy source.
Meigooni AS; Bharucha Z; Yoe-Sein M; Sowards K
Med Phys; 2001 Dec; 28(12):2568-75. PubMed ID: 11797962
[TBL] [Abstract][Full Text] [Related]
25. Theoretical and experimental determination of dosimetric characteristics for ADVANTAGE Pd-103 brachytherapy source.
Meigooni AS; Dini SA; Awan SB; Dou K; Koona RA
Appl Radiat Isot; 2006 Aug; 64(8):881-7. PubMed ID: 16713277
[TBL] [Abstract][Full Text] [Related]
26. The use of cylindrical coordinates for treatment planning parameters of an elongated 192Ir source.
Patel NS; Chiu-Tsao ST; Fan P; Tsao HS; Liprie SF; Harrison LB
Int J Radiat Oncol Biol Phys; 2001 Nov; 51(4):1093-102. PubMed ID: 11704334
[TBL] [Abstract][Full Text] [Related]
27. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy with various seed models.
Thomson RM; Rogers DW
Med Phys; 2010 Jan; 37(1):368-76. PubMed ID: 20175499
[TBL] [Abstract][Full Text] [Related]
28. Determination of dosimetric characteristics of OptiSeed(TM) a plastic brachytherapy (103)Pd source.
Wang Z; Hertel NE
Appl Radiat Isot; 2005 Sep; 63(3):311-21. PubMed ID: 15964196
[TBL] [Abstract][Full Text] [Related]
29. Monte Carlo dosimetry of the VariSource high dose rate 192Ir source.
Wang R; Sloboda RS
Med Phys; 1998 Apr; 25(4):415-23. PubMed ID: 9571607
[TBL] [Abstract][Full Text] [Related]
30. Dosimetric characterization of radioactive sources employed in prostate cancer therapy.
Zilio VO; Joneja OP; Popowski Y; Chawla R
Brachytherapy; 2004; 3(4):201-14. PubMed ID: 15607152
[TBL] [Abstract][Full Text] [Related]
31. Investigation of dose distribution of TheraSeed 200 103Pd brachytherapy seed on coaxial cylindrical phantom shells using Monte Carlo simulation.
Camgöz B; Kumru MN
Ann Nucl Med; 2011 Jun; 25(5):371-9. PubMed ID: 21404137
[TBL] [Abstract][Full Text] [Related]
32. [Simulation of dose distribution in bone medium of
Ye KQ; Huang MW; Li JL; Tang JT; Zhang JG
Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Feb; 50(1):131-135. PubMed ID: 29483735
[TBL] [Abstract][Full Text] [Related]
33. Improved treatment planning for COMS eye plaques.
Astrahan MA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1227-42. PubMed ID: 15752905
[TBL] [Abstract][Full Text] [Related]
34. More accurate fitting of 125I and 103Pd radial dose functions.
Taylor RE; Rogers DW
Med Phys; 2008 Sep; 35(9):4242-50. PubMed ID: 18841874
[TBL] [Abstract][Full Text] [Related]
35. Dosimetric evaluation of the Fletcher-Williamson ovoid for pulsed-dose-rate brachytherapy: a Monte Carlo study.
Price MJ; Horton JL; Gifford KA; Eifel PJ; Jhingran A; Lawyer AA; Berner PA; Mourtada F
Phys Med Biol; 2005 Nov; 50(21):5075-87. PubMed ID: 16237242
[TBL] [Abstract][Full Text] [Related]
36. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103.
Rivard MJ; Butler WM; Devlin PM; Hayes JK; Hearn RA; Lief EP; Meigooni AS; Merrick GS; Williamson JF
Brachytherapy; 2007; 6(1):34-7. PubMed ID: 17284383
[TBL] [Abstract][Full Text] [Related]
37. Monte Carlo calculations and experimental measurements of dosimetric parameters of the IRA-103Pd brachytherapy source.
Sadeghi M; Raisali G; Hosseini SH; Shavar A
Med Phys; 2008 Apr; 35(4):1288-94. PubMed ID: 18491522
[TBL] [Abstract][Full Text] [Related]
38. Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy.
Williamson JF; Butler W; Dewerd LA; Huq MS; Ibbott GS; Mitch MG; Nath R; Rivard MJ; Todor D;
Med Phys; 2005 May; 32(5):1424-39. PubMed ID: 15984693
[TBL] [Abstract][Full Text] [Related]
39. A Monte Carlo investigation of the dosimetric characteristics of the VariSource 192Ir high dose rate brachytherapy source.
Karaiskos P; Angelopoulos A; Baras P; Sakelliou L; Sandilos P; Dardoufas K; Vlachos L
Med Phys; 1999 Aug; 26(8):1498-502. PubMed ID: 10501049
[TBL] [Abstract][Full Text] [Related]
40. (144)Ce as a potential candidate for interstitial and intravascular brachytherapy.
Zilio VO; Joneja OP; Popowski Y; Bochud FO; Chawla R
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):585-94. PubMed ID: 15890604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
